HIV cure researchers are energized by news of another case of remission and the development of new tools that could help researchers evaluate how well other cure strategies are working.

Therapeutic antibodies against SARS-CoV-2 were developed faster than any other intervention, but their use remains limited. What lessons are there for the development of other monoclonal antibody products, including those for HIV?

An interview with Bali Pulendran on how adjuvants might extend the durability of mRNA-based vaccine protection.

Clinical research data is precious. The IAVI DataSpace platform seeks better ways to store, manage, and share this information securely so it can be used to advance medical research.

With pluck, persistence, and scientific prowess, more countries are gearing up to develop and produce the vaccines of the future.

COVID-19 has inspired many books about pandemic prevention, but reports show the world isn’t any better prepared today than it was before.

Scientists explain why a cytomegalovirus-vectored vaccine candidate, nearly 20 years in the making, produces promising results in monkeys. Will the same be true in humans?

Right now in vaccine research, mRNA has the momentum. For HIV, there are currently several formulations of experimental vaccines in early-stage human clinical trials. Apart from some overlap in strategy, they have one main thing in common — they rely on mRNA. This trend reflects the intense overall interest in mRNA-based vaccine development, given its…

After 25 years of IAVI Report, we’re making a few changes. In 2020, life changed for many across the globe. As SARS-CoV-2 began its deadly march through humankind, countries entered lockdown, offices and schools closed, and many of us who weren’t on the so-called front lines of the pandemic were largely sheltered within our homes.…

A conversation with Jon Cohen about what made writing about this pandemic different and what stories are still to be told.